A57S

Category 5 — IDR ExclusionConflictingCytoplasmic · predictedEditorial

Alanine → Serine at position 57 · N-terminal intrinsically disordered region (1-86) · WFS1 (Wolframin)

Ala→Ser p57 IDR AM=0.08 ddg=+0.1 pLDDT=27. ClinVar Conflicting evidence. Atlas mechanism: see structural analysis.

Interactive 3D Structure

Wild-type reference

Wild-type A57 — native residue, no strong sidechain contacts

Fullscreen ↗

DynaMut2 mutant · A57S

Mutant S57 — energy-minimized; local contact network preserved

Fullscreen ↗

Computational Predictions

DynaMut2 ΔΔG

0.10kcal/mol

Stabilising — mild

AlphaMissense

0.081

LBen

AlphaFold pLDDT

model confidence

Schema

Cat 5

Category 5 — IDR Exclusion

Clinical Evidence

ClinVar classificationConflicting classifications of pathogenicity

Review statuscriteria provided, conflicting classifications

Associated conditions(no specific conditions catalogued)

InheritanceConflicting ClinVar classifications.

Population frequency (gnomAD v4)Ultra-rare · AF 0.0074%

cDNA changec.169G>T

ClinVar accessionVCV000215374

Last evaluated2025/06/19 00:00

Observed at very low frequency in gnomAD.

Structural Context

Position analysis: ALA58 (2.4 Å — A58V/T), ASP56 (2.5 Å). pLDDT 27 deep IDR. Multi-substitution at 57 (A57S, A57T). The Atlas's neighbor extraction surfaces this variant's contacts and connects them to the broader multi-variant target landscape.

Amino-acid chemistry

polarity into IDR

Position in the protein

N-terminal IDR

Druggability Assessment

Cat 5 IDR — see structural prose. AlphaMissense below threshold (AM under-call class) but mechanism is structurally identified. Therapeutic strategy: site-directed at contacts identified above, or wet-lab validation if pLDDT borderline/below 50.

Why this matters

Position 57 multi-substitution IDR cluster.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the A57S PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download A57S PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1–890 · Wolframin

Region1–321 · Interaction with ATP6V1A

Region1–86 · Disordered